How should I explain the cardiovascular risks of romosozumab (Evenity) to the family of a patient who is at high risk for cardiovascular events?

Explaining Cardiovascular Risks of Romosozumab to High-Risk Patients and Families

For patients at high cardiovascular risk, you must clearly explain that romosozumab carries an FDA black box warning for increased heart attacks and strokes, and should NOT be used if the patient has had a heart attack or stroke within the past year 1.

Key Points to Communicate

The Specific Risk Data

When explaining the cardiovascular concerns to the family, present these concrete facts:

• In clinical trials comparing romosozumab to alendronate (a common osteoporosis medication), romosozumab showed a 1.9 times higher risk of cardiovascular events (heart attacks, strokes, or cardiovascular death) 2
• This increased risk was observed specifically when compared to active treatment with bisphosphonates, not placebo
• The FDA has issued specific safety warnings based on this finding 2

Absolute Contraindications to Emphasize

Make it crystal clear that romosozumab cannot be started if the patient has:

• Had a heart attack within the past 12 months
• Had a stroke within the past 12 months 1

Risk-Benefit Discussion Framework

Structure your conversation this way:

1. Acknowledge the fracture risk severity:

• Explain that romosozumab is reserved for patients at "very high risk" for fractures—meaning those with previous osteoporotic fractures or multiple risk factors
• Emphasize that untreated severe osteoporosis carries its own mortality risk from hip and vertebral fractures

2. Present the cardiovascular concern honestly:

• State that in one major trial, there was a higher rate of major adverse cardiac events (MACE) in romosozumab-treated patients compared to those on alendronate 1
• Explain that this finding has led to FDA warnings and careful patient selection requirements

3. Contextualize with recent evidence:

• Note that more recent analyses and real-world studies have shown conflicting results, with some finding no significant cardiovascular differences 3, 4
• However, emphasize that the FDA warning takes precedence in clinical decision-making 1

Monitoring Requirements

If proceeding with treatment despite cardiovascular risk factors (but not absolute contraindications), explain that:

• The patient must be monitored for signs and symptoms of heart attack (chest pain, shortness of breath, jaw/arm pain) and stroke (sudden weakness, speech difficulty, vision changes)
• If a heart attack or stroke occurs during treatment, romosozumab must be stopped immediately 1
• The family should seek emergency care immediately if these symptoms develop

Alternative Treatment Discussion

Always present the alternative: Explain that other osteoporosis medications exist with different risk profiles:

• Bisphosphonates (like alendronate) have decades of safety data
• Denosumab is another option, though requires careful management if discontinued
• Teriparatide is available for high-risk patients, though with different considerations 2

Common Pitfalls to Avoid

• Don't minimize the FDA black box warning—this is the highest level of safety alert and must be taken seriously
• Don't use romosozumab in patients with recent MI/stroke regardless of fracture risk severity
• Don't fail to document the detailed risk-benefit discussion, including why romosozumab was chosen over alternatives or why it was avoided
• Don't forget that romosozumab is limited to 12 monthly doses because its bone-building effect diminishes after that 2

Documentation Language

Document that you explained:

1. The FDA black box warning for cardiovascular events
2. The 1.9-fold increased hazard ratio compared to alendronate
3. Absolute contraindications (recent MI/stroke within 1 year)
4. Warning signs requiring emergency evaluation
5. Alternative treatment options discussed
6. The family's questions and understanding of these risks

The decision ultimately requires weighing severe fracture risk against cardiovascular risk, but the FDA contraindications are absolute 1. In patients with other cardiovascular risk factors (hypertension, diabetes, smoking, family history) who don't have absolute contraindications, the decision becomes more nuanced, but the cardiovascular concerns must be front and center in the shared decision-making process.